Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹696 Cr revenue.
COGS 30.3%, employees 11.6%.
“We would like to reiterate our guidance of achieving around 20% of annual revenue growth with EBITDA margins in the range of 33 to 35%.”
“Our journey towards 1,000 crore revenue by financial year twenty seven is well on track”
“Revenue for the quarter stood at rupees 200 crores, reflecting a growth of 20% year on year at 38% subsequently.”
Historical valuation data not available.
Revenue segment breakdown not available.
| (₹ Cr) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | ₹696 Cr +22.1% | ₹570 Cr +23.7% | ₹461 Cr -13.0% | ₹530 Cr |
| Other Income | ₹10 Cr -7.7% | ₹11 Cr +12.1% | ₹9 Cr +25.2% | ₹8 Cr |
| Total Income | ₹706 Cr +21.6% | ₹581 Cr +23.5% | ₹470 Cr -12.5% | ₹538 Cr |
| COGS | ₹211 Cr -4.8% | ₹222 Cr +22.6% | ₹181 Cr -7.7% | ₹196 Cr |
| ₹458 Cr +10.2% | ₹415 Cr +19.7% | ₹347 Cr +5.0% | ₹330 Cr | |
| Profit Before Tax | ₹248 Cr +50.0% | ₹166 Cr +34.2% | ₹123 Cr -40.4% | ₹207 Cr |
| ₹61 Cr +29.9% | ₹47 Cr +38.5% | ₹34 Cr -39.3% | ₹55 Cr | |
| Net Profit | ₹188 Cr +57.8% | ₹119 Cr +32.6% | ₹90 Cr -40.8% | ₹152 Cr |
| Other Comprehensive Income | (₹0.13 Cr) ↓ Decline | ₹2 Cr ↑ Recovery | (₹1 Cr) -299.0% | (₹0.32 Cr) |
| EPS | ₹23.35 | ₹14.80 | ₹11.16 | ₹18.86 |
| Diluted Shares | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹8 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Supriya Lifescience Limited has informed the Exchange about Schedule of meet
Supriya Lifescience Limited has informed the Exchange about Transcript
Supriya Lifescience Limited has informed the Exchange about Link of Recording
Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication
Supriya Lifescience Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Press Release - Audited Financial Results for quarter and year ended March 31, 2026".
Supriya Lifescience Limited has informed the Exchange about Schedule of meet
Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Update on inspection by United States Food & Drug Administration (USFDA)
Supriya Lifescience Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Reg...
Supriya Lifescience Limited has informed the Exchange regarding Notice of Postal Ballot
The Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Reg...
Supriya Lifescience Limited has informed the Exchange about Transcript
Supriya Lifescience Limited has informed the Exchange about Link of Recording
Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication of Unaudited Financial Results of the Company for quarter and nine months ended December 31, 2025 is enclosed.
Supriya Lifescience Limited has informed the Exchange regarding a press release dated February 10, 2026, titled "Press Release- Unaudited Financial Results for the Quarter and Nine Months ended Decemb...